fbpx
Skip to main content

FDA Market Clears Erchonia’s FX 635 Laser for Chronic Low Back Pain

First and Only FDA Market Cleared Low-Level Laser Treatment Option

Erchonia Corporation announces another successful clinical trial that has resulted in the granting of an FDA 510(k) market clearance for chronic low back pain of musculoskeletal origin. This grants another first for Erchonia, which started the low-level laser category in January 2002.  That year, the FDA issued its first 510(k) market clearance for any low-level laser based on Erchonia’s clinical trial for chronic neck and shoulder pain.

This new indication for chronic low back pain is the only laser to be market cleared by the FDA.  Erchonia’s long history and dedication to the science of low-level laser therapy has led to 22 FDA 510(k) market clearances based on their patented laser systems.

About the study:  Erchonia through the pre-IDE process worked with the U.S. FDA on study design and success criteria. The success criteria were defined as a minimum of a 30% decrease in chronic low back pain and 35% of patients in the treated group would experience the minimum pain reduction compared to the placebo group.  Overall, 72% of patients met the success criteria. Steven Shanks, President of Erchonia stated, “We believe we have demonstrated that the use of non-thermal lasers has proven to be a far better option for treating low back pain than that of opioids or NSAIDS.”

A recent study published in JAMA in 2018 titled The Space Randomized Clinical Trial looked at chronic low back pain with opioids and NSAIDS over 1 year. Opioids demonstrated a 30% reduction in pain and NSAIDS proved a 34.5% reduction in pain. The publication concluded that “Results do not support initiation of opioid therapy for moderate to severe back pain or hip or knee osteo arthritis pain”.

Taking into consideration the minimal effectiveness (30%) and the opioid crisis along with the side effects of NSAIDS for chronic low back pain, doctors and patients may now have safer, more effective option for chronic low back pain of musculoskeletal origin that has been proven successful with no side effects or adverse events.

Erchonia would like to thank doctors Greg Roche, Trevor Berry and Paul Quarneri for their dedication to the science of low-level laser therapy and for helping them document this placebo-controlled, randomized, double-blind, parallel group, multi-center clinical study.

For more information, please visit https://www.erchonia.com.

About Erchonia

A small family company is changing the world with the most advanced non-invasive lasers on the market. Erchonia went from starting in a small garage in 1996 to selling their product in over 50 different countries around the world in 2018. Erchonia has been passionate about researching and developing low level lasers since the beginning with over (15) FDA clearances for treating chronic pain and promoting fat loss. As this family has grown so has the world of non-invasive drug-free healthcare solutions.

Lunula Laser targets nail fungus WKRC June 2018

Click Here for the Full Story

There’s something new to keep your toes healthy this summer sandal season. It’s a new laser to help your toenails look a whole lot better.

This “flip flop season”, Melinda Wigginton has a new “weapon” to keep her toes in tip top shape.

“It is a new laser that has been FDA cleared to target toenail fungus,” said Dr. Ruth Ann Cooper, a Podiatrist.

“My toenails were discolored but they started cracking and breaking,” said Wigginton.

So, Wigginton made the decision to work with Dr. Cooper. She’s a podiatrist who’s one of the first in the country to offer patients the Lunula Laser.

“It is painless, it is easy, and it’s effective,” said Dr. Cooper.

The laser stimulates blood flow and oxygen to promote new, clear nail growth.

The laser is using photochemistry to target the fungus. Photochemistry is the science of light and color.

Each treatment takes about 12 minutes, and you do need more than one treatment with the laser for the best results.

The good news is that after the procedure is completed, you can come back and use it as sort of preventative maintenance along with products to promote healthy toenails.

The laser is about $300 per session and it’s not covered by medical insurance plans.

 

 

OPIOID CRISIS – Dr. Dan Murphy’s Solution for Pain & Inflammation

 
 

 

Dynamic Chiropractic June 2018

 

Pain is a huge problem in America, and all Americans know that opiate drugs are not the solution to our pain problem. In her 2014 book, A Nation in Pain, Judy Foreman claims, “Out of 238 million American adults, 100 million live in chronic pain.” (1) A conservative estimate of the direct costs and lost productivity resulting from this pain is up to $635 billion yearly (2). Chronic pain affects every region of the body. Quantifying the anatomical regions for American’s chronic pain shows that the most significantly affected region is the lower back followed by (3):

 

Lower-Back Pain 28.1%

Knee Pain 19.5%

Severe Headache 16.1%

Neck Pain 15.1%

Shoulder Pain 09.0%

Finger Pain 07.6%

Hip Pain 07.1%

 

There is a high level of satisfaction by patients who seek treatment for spinal and other pain syndromes from chiropractors (4). It is argued that the physiological basis for the chiropractic benefit for pain suffers is the closure of the “pain gate.” (5) Yet, chiropractors often also use adjuncts to spinal adjusting for the treatment of pain syndromes. The rational for such adjuncts is that inflammation alters the threshold of the nociceptive system.

Most pain is a chemical event. Inflammatory chemicals irritate pain nerves. Understanding of the inflammatory chemical nature of pain was awarded the Nobel Prize in Physiology or Medicine in 1982. In 2007, the journal Medical Hypothesis states (6): 

“Every pain syndrome has an inflammatory profile consisting of the inflammatory mediator that are present in the pain syndrome. “The key to treatment of Pain Syndromes is an understanding of their inflammatory profile.” “The origin of all pain is inflammation and the inflammatory response.”

“Irrespective of the type of pain whether it is acute or chronic pain, peripheral or central pain, nociceptive or neuropathic pain, the underlying origin is inflammation and the inflammatory response.”

“Irrespective of the characteristic of the pain, whether it is sharp, dull, aching, burning, stabbing, numbing or tingling, all pain arises from inflammation and the inflammatory response.

Although there are many inflammatory chemicals related to pain, the best understood is an eicosanoid hormone-like chemical called Prostaglandin E2 (PGE2). As depicted in the graph above, PGE2 is derived from the omega-6 fatty acid Arachidonic Acid (AA). AA itself is derived from vegetable oils, primarily corn, soy, sunflower, safflower, cottonseed, peanut, and canola oils. As such, consumption of any of these vegetable oils is inflammatory and related to pain thresholds. When one consumes meat derived from animals fed any of these products one is consuming high quantities of pre-formed AA, increasing the likelihood of suffering from pain syndromes (7).

In the pain references text, Weiner’s Pain Management, published by the American Academy of Pain Management, it notes the following as a major cause of the modern epidemic of pain (8):

“Changes in the modern diet are largely responsible for the increasing incidence of essential fatty acid imbalances and deficiencies.”

“The ratio of omega-6 to omega-3 fats has changed dramatically due to the widespread use of vegetable oils (mostly n-6 fats) in cooking and to the processing of oils.”

“Historical estimates place the ratio of omega-6 to omega-3 oils at nearly 1:1 for prehistoric humans.”

By the turn of last century (1900), the ratio had increased to about 4:1. The current American ratio is about 25:1.

This text indicates that 100 years ago Americans consumed about two pounds of these inflammatory vegetable oils yearly; the current approximate level of consumption in 25 pounds yearly. The results are an explosion of inflammatory conditions, including pain, which are treated with non-steroidal anti-inflammatory drugs (NSAIDs).

As noted in the graph below on left, the conversion of the omega-6 fatty acid AA into inflammatory (and pain producing) PGE2 is controlled by a series of enzymes called cyclooxygenase, often abbreviated COX. The 1982 Nobel Prize details how the COX enzymes are inhibited by a group of drugs, mentioned in Weiner’s text, non-steroidal anti-inflammatory drugs (NSAIDs). However, when these drugs (NSAIDs) are taken for chronic pain, there are many serious side effects. In 2003, the journal Spine states (9):

“Adverse reactions to non-steroidal anti-inflammatory (NSAID) medication have been well documented.”

“Gastrointestinal toxicity induced by NSAIDs is one of the most common serious adverse drug events in the industrialized world.”

In 2006, the journal Surgical Neurology states (10): Blockage of the COX enzyme inhibits the conversion of arachidonic acid to the very pro-inflammatory prostaglandins that mediate the classic inflammatory response of pain.

Almost all patients who take the long-term NSAIDs will have gastric hemorrhage, 50% will have dyspepsia, 8% to 20% will have gastric ulceration, 3% of patients develop serious gastrointestinal side effects, which results in more than 100,000 hospitalizations, an estimated 16,500 deaths, and an annual cost to treat the complications that exceeds 1.5 billion dollars.

“NSAIDs are the most common cause of drug-related morbidity and mortality reported to the FDA and other regulatory agencies around the world.”

Other side effects attributed to the consumption of NSAIDs includes end-stage renal disease, heart attacks, strokes, erectile dysfunction, hearing loss, deep vein thrombosis, and increased risk of Alzheimer’s disease

A modern and proven effective non-drug approach to the treatment of pain, especially chronic pain, is the supplementation of omega-3 fatty acids, especially eicosapentaenoic acid (EPA), found in fish oil. EPA is a precursor to the anti-inflammatory eicosanoid Prostaglandin E3 (PGE3). The only drawback to this approach (supplementation with high-dose quality fish oil) is the optimum benefit takes months of ingestion (10, 11, 12).

Is there a way to inhibit the COX enzymes for the treatment of both acute and chronic pain that is quick, effective, and safe, without side effects? The answer is yes, the application on low-level laser therapy.

A search of the National Library of Medicine using PubMed (3/29/2018) with the search terms “low-level laser therapy AND pain” locates 1,161 citations. A search of the National Library of Medicine using PubMed (3/29/2018) with the search terms “low-level laser therapy AND NSAID” locates 66 citations. Laser Therapy reference texts emphasize the ability of low-level laser to effectively treat pain without side effects. For example, the 2010 book titled The New Laser Therapy Handbook states (13):

“The effect of laser photon therapy [LPT] on inflammation is covered in many chapters of this book. The anti-inflammatory effect of LPT has been widely studied. LPT seems to have a similar effect to steroids and NSAIDs, but without the severe side effects of these very common pharmaceuticals.”

The authors indicate that laser therapy for pain control is enhanced if the laser is applied to both the painful region and the nerve roots that innervate the painful region. Other studies further emphasize the importance of applying the laser to the nerve roots. A particularly interesting study resulted in the successful management of 35 patients suffering from carpal tunnel syndrome; the laser therapy was not applied to the wrist but rather to the nerve roots that innervate the wrist (14).

There are advantages to being capable of doing both regions simultaneously.

An important study documenting the ability of low-level laser therapy to inhibit COX enzymes resulting in a significant reduction in inflammatory chemicals was published not in a laser journal, but rather in a cancer journal, Support Care Cancer (15). After exposing animals to caustic inflammatory chemicals (fluorouracil), they were randomly assigned to either a control group (no laser) or to low-level laser therapy. At four time points, tissue samples were immunohistochemistry assessed from both groups by a blinded examiner. The authors found that the laser therapy group “was accompanied by a significantly lower level of COX-2 staining.”

Interestingly, increasing the laser fluence (increasing the milliwatts by 3X) did not further enhance the clinical outcomes. In contrast, such higher laser fluence reduced the clinical benefit to the level of the control group (no laser). This suggests that laser therapy is not linear, but rather hormetic (bell shaped curve). The authors concluded:

“The tissue response to laser therapy appears to vary by dose. Low-intensity laser therapy appears to reduce the severity of mucositis, at least in part, by reducing COX-2 levels and associated inhibition of the inflammatory response.”

Thousands of chiropractors are using low-level laser therapy as an adjunct to chiropractic and nutrition in the management of their pain patients. Low-level laser therapy is quick, effective, and safe, and earned FDA clearance in 2002. (Erchonia Corporation www.Erchonia.com)

 

 

Dan Murphy, DC, DABCO

www.DanMurphyDC.com

REFERENCES:

1) Foreman J; A Nation in Pain, Healing Our Biggest Health Problem; Oxford University Press; 2014.

2) Pho, K; USA TODAY, The Forum; September 19, 2011; pg. 9A.

3) Wang S; Why Does Chronic Pain Hurt Some People More?; Wall Street Journal; October 7, 2013.

4) Adams J, Peng W, Cramer H, Sundberg T, Moore C; The Prevalence, Patterns, and Predictors of Chiropractic Use Among US Adults; Results From the 2012 National Health Interview Survey; Spine; December 1, 2017; VOL. 42; No. 23; pp. 1810–1816.

5) Kirkaldy-Willis WH, Cassidy JD; Spinal Manipulation in the Treatment of Low back Pain; Canadian Family Physician; March 1985; Vol. 31; pp. 535-540.

6) Omoigui S; The biochemical origin of pain: The origin of all pain is inflammation and the inflammatory response: Inflammatory profile of pain syndromes; Medical Hypothesis; 2007, Vol. 69; pp. 1169–1178.

7) Hyman M; Eat Fat, Get Thin: Why the Fat We Eat Is the Key to Sustained Weight Loss and Vibrant Health; Little, Brown and Company, 2016.

8) Boswell M, Cole BE, editors; Weiner’s Pain Management: A Practical Guide for Clinicians; American Academy of Pain Management; Seventh Edition; 2006, pp. 584-585.

9) Giles LGF, DC, PhD; Reinhold Muller R; Chronic Spinal Pain: A Randomized Clinical Trial Comparing Medication, Acupuncture, and Spinal Manipulation; Spine; July 15, 2003; Vol. 28; No. 14; pp. 1490-1502.

10) Maroon JC, Bost JW; Omega-3 Fatty acids (fish oil) as an anti- inflammatory: an alternative to nonsteroidal anti-inflammatory drugs for discogenic pain; Surgical Neurology; 65 (April 2006); pp. 326–331.

11) Cleland LG, James MJ, Proudman SM; Fish oil: what the prescriber needs to know; Arthritis Research & Therapy; 2006; Vol. 8; No. 1; 202. 12) Goldberg RJ, Katz J; A meta-analysis of the analgesic effects of omega- 3 polyunsaturated fatty acid supplementation for inflammatory joint pain; Pain; May 2007; Vol. 129; No. 1-2; pp. 210-223.

13) Tuner J, Hode L; The New Laser Therapy Handbook, Prima Books, 2010. 14) Wong E, Lee G, Zucherman J, Mason DT; Successful management of female office workers with “repetitive stress injury” or “carpal tunnel syndrome” by a new treatment modality–application of low-level laser; International Journal of Clinical Pharmacology and Therapeutics; April 1995; Vol. 33; No. 4; pp. 208-211.

15) Lopes NN, Plapler H, Chavantes MC, Lalla RV, Yoshimura EM, Alves MT; Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols; Support Care Cancer; November 2009; Vol. 17; No. 11; pp. 1409-1415.

 

Daniel Murphy, DC, DABCO is a well-recognized, award winning chiropractor and a popular instructor who teaches internationally while maintaining a part-time clinical practice. He has taught over 1,610 twelve-hour postgraduate continuing education classes. He also serves as part-time undergraduate faculty professor at Life Chiropractic College West, where he is currently teaching classes to seniors in the management of spinal disorders. He has taught post-graduate classes for a long list of chiropractic colleges and individual programs. He is a contributing author to several books and a quarterly columnist in the American Journal of Clinical Chiropractic. From 2003 – 2009, Daniel Murphy, DC, DABCO served as the Vice President of the International Chiropractic Association. In 2014, he was awarded the Lifetime Achievement Award from the International Association of Functional Neurology and Rehabilitation (IAFNR).

 

 

 

 

Laser Collaboration, 33 Partners from Around the Globe Represented ~ Erchonia 2018

World’s Laser Therapy Advocates Convene in Orlando, FL, USA on May 3rd-4th, 2018

 

MELBOURNE, FLA. (PRWEB) MAY 01, 2018 We are verging on a global precipice: the increase in the number of debilitating brain diseases is growing exponentially, obesity rates are skyrocketing, more than ever before, patients who experience pain are becoming addicted to opioids. Traditional medicine is on the brink of a revolution in the healing arts; this revolution is called low-level laser therapy (3LT®)!  Florida based low-level laser technology manufacturer Erchonia Corporation will host their annual Partner’s Meeting at the Hyatt Regency Orlando on May 3rd-4th, 2018.  With over 2 decades of published laser research and 15 FDA 510(k)s on laser therapy leading up to this conference, the advancements in medicine and laser therapy will impress attendees and international partners alike.

World renowned researchers and scientists will prepare substantiated lectures reviewing existing low-level laser FDA market clearances and disclose (3) new, Level (I) clinical trials, their applications and the long-term developments for low-level laser therapy.  The new laser application line-up includes brain diseases, low back pain and peripheral neuropathy just to name a few.

“We are very excited by the growth that we are achieving across the world.  We are confident Erchonia Lasers will continue to prove to be ‘THE’ prominent choice for those seeking laser therapy.  The impeccable presenter line-up we have scheduled is like none other.” -Charlie Shanks, VP of Erchonia Corp

Researchers, International Partners and Erchonia Laser Enthusiasts are invited to share in a goldmine for laser therapy.  The educational meeting will be followed by a cocktail reception at The Red Coconut Club at Universal City Walk where attendees will meet the presenters from around the globe.

*New indications discussed during this event are going through FDA clinical trials.  Go to www.ClinicalTrials.gov, search “Erchonia”.  Devices for new indications have not been FDA market cleared.  New devices will not be introduced to market until FDA 510(k) is obtained.

Founded in 1996, Erchonia Corporation is the world leader in low-level laser technology. The company created the low-level laser category in 2002 when it received an FDA 510(k) market clearance for low-level lasers. Erchonia was the first company to receive this FDA 510(k) distinction. For more information, visit www.erchonia.com or call 888-242-0571.

For additional information, image and interview requests, contact Erchonia Corporation (888) 242-0571.

Related Links https://www.Erchonia.com

 

https://www.prweb.com/releases/2018/05/prweb15452126.htm

Low Level Laser Therapy for 360°- Degree Body Sculpting

Michael H. Gold, M.D., FAAD from Gold Skin Care Center presenting Thursday 5th April @ 10:00AM at AWMC 2018 ~ Monaco.

 

 

Verjú LLLT by Erchonia, FDA Cleared for circumferential reduction of the waist, hips and thighs and temporary reduction in the appearance of cellulite will be featured on the programme at the Aesthetic and Anti-Aging Medicine Congress 2018.  The Verjú laser produces a low-level output that has no thermal effect on the body’s tissue.  Its unique technology does not kill or damage fat cells, but instead creates a transitory pore in each cell for the fat to leak out, which is then processed naturally through the lymphatic system, leaving the cell intact for important endocrine function.

The 510(k) is a premarketing submission to the FDA that demonstrates that the device marketed is safe and effective. The premarket approval for the 510(k) is the most rigorous type of device marketing application accepted by the FDA.  The Verjú Laser System obtained its 1st 510(k) clearance in 2012.

Verjú Study Results – NO lifestyle changes – Published in American Journal of Cosmetic Surgery for Body Contouring and Lasers in Surgery in Medicine for Appearance of Cellulite.  There were no adverse events in either study.

A world leading Dermatologist and Cosmetic Surgeon, Michael H. Gold, M.D., FAAD, will present Thursday 5th April @ 10:00AM.  Dr. Gold’s message is ‘A Better You’!

Simon Ramshaw, Managing Director of Erchonia Lasers LTD. comments, “Having an expert such as Dr. Gold recognize the quality of our research and the clinical utility of Erchonia’s Verjú Laser

System is truly an honor.  Quality clinical research is pivotal for our overall success.  Erchonia’s commitment to research stands out in aesthetic medicine.”

Founded in 1996, Erchonia Corporation is the world leader in low-level laser technology. The company created the low-level laser category in 2002 when it received an FDA 510(k) market clearance for low-level lasers. Erchonia was the first company to receive this FDA 510(k) distinction. For more information, visit www.erchonia.com or call 888-242-0571.

For additional information, image and interview requests, contact Erchonia Lasers Ltd at +44(0)1491 821135.

Related Links https://www.Erchonia.com

 

 

WHAT STUDIES SAY ABOUT CLASS IV LASERS & SPECIFICALLY, THEIR IMPACT ON CANCER CELLS

 

 
 

 

The National Cancer Institute (NCI) reports that 39.6 percent of all Americans will receive a cancer diagnosis at some point in their lives. The NCI goes on to explain that cancer is one of the top causes of death across the globe, with new diagnoses expected to increase twofold-from 14 million to 22 million-within the next twenty years. Because of statistics like these, many researchers are working diligently to learn more about cancer cells, as well as to discover what makes them form and grow. One area of study they’ve spent some time in recently involves the use of medical lasers. Class IV lasers, specifically.

 

Lasers and cancer cell research

 

One such study was published in the American Academy of Physical Medicine and Rehabilitation’s PM&R Journal in November of 2017. This particular piece of research involved the use of two different types of cells: saos-2 osteoblast-like osteosarcoma cells and A549 human lung carcinoma cells.

After preparing the culture plates, each one was subjected to laser irradiation either one, two, or three times with d:YAG lasers, the power output ranging from 0.5 to 3 watts. Approximately 24 hours after receiving the last laser application, the plates were analyzed to see what change, if any, existed to the cells.

It was during this analysis that researchers discovered that, the more laser applications a specific culture plate received, the higher the proliferation rate, or the more these cancerous cells increased in number, when compared to control plates. Thus, they concluded that this type of laser therapy “could activate precancerous cells or increase existing cancerous tissue.”

Other studies have found similar results. For instance, in November of 2009, BMC Cancer published a study involving mice with melanoma cells. For purposes of this particular study, some of the mice served as the control, some were exposed to three sessions of irradiation lasting 60 seconds each (dose 150 J/cm2), at the rate of one per day for three days, and the rest were exposed to three sessions of irradiation lasting 420 seconds (dose 1050 J/cm2).

Upon conclusion of the final session, each mouse was analyzed to see if there were changes in the melanoma cells. The group that was exposed to 60 seconds of lower level laser therapy (150 J/cm2) showed results “not significantly
different from the controls.”

However, the same could not be said for the other mice, the ones exposed to the more powerful laser doses (1050 J/cm2), as the researchers reported that they experienced “significant increases in tumor volume, blood vessels and cell abnormalities compared to other groups.

 

 

So, are medical lasers safe?

 

Findings like these underline the importance of using lasers with the appropriate strength and within the appropriate
class to obtain the desired medical result without risking the patient’s health and safety.

This involves using lasers within the lower classifications (Class I, 11, or Ill) as many of these have been found safe for enhancing health and wellness without impacting a person’s risk of cancer or increasing their cancerous cell activity. It also means using lasers from an FDA approved company, thus  protecting yourself as well as your patients.

 

Class IV medical lasers defined:

 

The U.S. Food and Drug Administration (FDA) adds to the topic by sharing that lasers can be placed in one of four hazard classes, ranging from Class I to Class IV, with some of these classes containing subclasses within them. However, For simplicity’s sake, the FDA says that the best way to understand the differences is, “the higher the class, the more powerful the laser is and the greater the potential to pose serious injury if used improperly.” Because these are the highest level of lasers, this causes many to question what impact they may have on the human body. Specifically, some researchers have set out to discover what effect they may have on cancerous and precancerous cells.

 

 

Sources
1. The National Cancer Institute – https://www.cancer.gov/about-cancer/understanding/statistics

2. American Academy of Physical Medicine and Rehabilitation’s PM&R Journal in November of 2017 – https://www.ncbi.nlm.nih.gov/pubmed/29160001

3. BMC Cancer – https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-9-404

4. U.S. Food and Drug Administration (FDA) – https://www.fda.gov/Radiation-EmittingProducts/RadiationEmittingProductsandProcedures/HomeBusinessandEntertainment/LaserProductsandInstruments/default.htm

Disclaimer
*The material presented is being made available for educational purposes only. This article was compiled based on research collected through online and medical publications. Erchonia is not liable for any use you may make of such information. The views are presented to inform readers of possible dangers of high powered lasers. All of the opinions presented do not present any medical claims not currently stated through government agencies. The approaches, information and opinions may not be applicable to all cases, and each health care provider must use their own independent medical judgment in treating any individual patient or condition.

 

5 Myths of Laser Body Contouring

Like most other popular weight loss procedures, laser body contouring has its share of misconceptions. In an effort to clear up some of those myths, we’ll look at five of the most common and give you the truth of the matter.

  1. Laser body contouring is too expensive.
    When compared to traditional surgical liposuction, which runs anywhere from $1,500 to $7,500, the cost of laser body contouring isn’t so bad after all at $1,000 to $2,500.
  2. Laser body contouring is painful.
    With most patients having laser body contouring treatments in their plastic surgeon’s office and then going on about their day, this myth is easily discounted. Laser contouring doesn’t require any kind of anesthesia—in fact, most patients say it feels like nothing or like a flashlight shining on them. When compared to traditional inpatient liposuction with all its incisions, bruising, and swelling, laser body contouring’s noninvasive techniques are much more easily tolerated.
  3. Laser body contouring takes a long time.
    Each session typically lasts 30 to 40 minutes. Each treatment typically involves 3 sessions per week over two weeks. That’s 6 sessions at 30 to 40 minutes each. The average American spends about the same amount of time watching television each weekend. You decide.
  4. Laser body contouring is dangerous.
    Unlike traditional liposuction, laser body contouring carries few risks. There are no incisions, no need for anesthesia, and no cause for antibiotics. There is no scarring involved. Laser body contouring is as safe as it gets in medical procedures—with the right tools, the right training, and the right hands on the tools, you have nothing to worry about.
  5. Laser body contouring doesn’t work.
    From the number of scientific studies to the number of happy, satisfied customers, it’s easy to see that this one is just plain wrong. Laser body contouring has been around for many years, and the positive results from patients can’t be denied. How well the treatment lasts depends on the patient’s willingness to watch diet and exercise and not allow themselves to pack the pounds back on. But the treatments in and of themselves are highly effective at helping patients lose unwanted fat deposits.

While laser body contouring may not be for everyone, there’s no need to believe all the false myths and misconceptions about it. Knowing the facts can help you make a better informed and educated decision. If you would like to learn more about laser body contouring, check out our My Zerona laser scanner.

How 3LT Can Help Our Equine Friends

Humans domesticated horses millennia ago, changing the way our ancestors traveled, fought, and survived. They are majestic, beautiful creatures built for speed and power. 

Sadly, one of the most serious and devastating diseases affecting horses, ponies, and other equine animals is laminitis. Let’s take a closer look at laminitis and how low-level laser therapy can give our equine companions a leg up.

What is Laminitis?

Laminitis describes a condition wherein the laminae—the tissues bonding the hoof wall to the pedal bone in a horse’s hoof—become weakened and inflamed from disruptions in blood flow, leading to tears in the structure supporting the pedal bone within the hoof. Laminitis typically occurs in a horse’s front feet. The condition is caused by various physical and metabolic issues, including:

  • An excessive intake of grain or grass
  • High levels of insulin
  • Enlargement of the pars intermedia in the pituitary gland
  • Impact from riding on hard surfaces
  • Stress from long distance travel

This can result in tremendous pain, lameness, and deterioration in the hoof. Left untreated, laminitis can cause the pedal bone to rotate and point downwards. In worst cases, the pedal bone will penetrate through the hoof wall.

Laminitis greatly reduces a horse’s usefulness, and many horse owners are forced to put down the horse to prevent further suffering.

Treating Laminitis

Many traditional treatments are expensive and time-consuming and don’t guarantee full recovery. These include changing your horse’s diet, providing greater hoof care, and moving your horse to a different enclosure featuring deep shavings or sand. Severe cases wherein the pedal bone has sunken through the hoof require surgical procedures involving tendon release, but this can put the horse at risk of infection or cause damage to surrounding structures.

Low-level laser therapy has been used in humans to treat joint pain, edema, soreness, and wounds, but veterinarians have extended these laser treatments to horses suffering from laminitis. Studies show that the photon energy in a low-level laser stimulates blood vessels in a horse’s foot, promoting greater circulation, better tissue nutrition, and ultimately faster healing. Laser therapy also greatly reduces the chance of infection or damage to surrounding areas as the procedure is entirely non-invasive.

Animal Health Options, a purveyor of innovative and effective supplements for animal wellness since 1990, has found success in incorporating low-level laser therapy into its treatment for laminitis. Horses undergo low-level laser sessions two to three times a week. This is coupled with:

  • A restrictive diet to reduce weight and make up for insulin resistance
  • Plenty of lying down to keep pressure off the affected feet
  • Visits with a farrier to trim hooves to correct the angle of the feet

Preventing Laminitis

One of the best ways to treat laminitis is to prevent it from happening altogether. While you can’t always predict your horse’s health, you can control parts of his environment, primarily his diet. Too much grain or lush green grass leads to excessive sugars stored in the hind gut. When these sugars are absorbed, the horse develops hyperinsulinemia (an overload of insulin), which can trigger laminitis. A bad diet can also lead to obesity, putting more pressure on your horse’s hooves. To keep your horse’s diet in check:

  • Feed your horse a high fiber, forage-based diet, comprising a mixture of mature grass, hay, and alfalfa. Vegetable oils can be included in this diet for added calories.
  • Carefully manage grazing. Considering grazing your horse at night, when sugar levels are lowest.
  • Avoid hard feed unless your horses are performing hard work.

Maintain a regular hoof trimming schedule for good hoof health. Your horse may also need specialist shoeing for proper support.

Zerona Laser Fat Attack – Muscular Development Magazine May 2010 Issue

Topical Fat-Buster:  Lose 7 Inches of Fat in 20 Minutes — No Bull!
By Dan Gwartney, MD

Zerona Laser in Fitness RX for Men May 2010 Issue

Topical Fat-Buster:  Lose 7 Inches of Fat in 20 Minutes-NO BULL
By Dan Gwartney, MD